 |
 |
 |
|
Better Work Productivity and Activity in Patients On Ombitasvir/Paritaprevir/Ritonavirand Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 (GT1) Chronic Hepatitis C - 2
|
|
|
Reported by Jules Levin
AASLD 2015, The Liver Meeting®, San Francisco, California, November 13-17
Yan Liu1, Yan Luo1, Xuan Liu1, Danielle Sullivan1, Timothy Juday1, Brian Conway2
1AbbVie Inc., North Chicago, IL, United States; 2Vancouver Infectious Diseases Centre, Vancouver, Canada







|
|
|
 |
 |
|
|